These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 32697374)

  • 41. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and emerging systemic treatment strategies for psoriasis.
    Laws PM; Young HS
    Drugs; 2012 Oct; 72(14):1867-80. PubMed ID: 22938141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
    Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A
    Front Immunol; 2018; 9():1668. PubMed ID: 30150978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis.
    Sun C; Xia J
    Minerva Med; 2020 Jun; 111(3):254-265. PubMed ID: 32166932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An overview of developing TNF-α targeted therapy for the treatment of psoriasis.
    Campa M; Ryan C; Menter A
    Expert Opin Investig Drugs; 2015; 24(10):1343-54. PubMed ID: 26289788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
    Campanati A; Molinelli E; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unmet needs in the treatment of psoriasis.
    Kragballe K; van de Kerkhof PC; Gordon KB
    Eur J Dermatol; 2014; 24(5):523-32. PubMed ID: 25115238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current treatment of psoriasis with biologics.
    Kunz M
    Curr Drug Discov Technol; 2009 Dec; 6(4):231-40. PubMed ID: 20025590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
    Wu KK; Lee MP; Lee EB; Wu JJ
    J Dermatolog Treat; 2020 Jun; 31(4):359-365. PubMed ID: 30900514
    [No Abstract]   [Full Text] [Related]  

  • 52. Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis.
    Wytsma J; Woo TE; Parsons L
    Skin Therapy Lett; 2024 May; 29(3):5-8. PubMed ID: 38781953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
    Mease PJ
    Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY; Chong WS; Tey HL
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
    Amin M; No DJ; Egeberg A; Wu JJ
    Am J Clin Dermatol; 2018 Feb; 19(1):1-13. PubMed ID: 29080066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Trial and Registry Data.
    Gooderham M; Papp K
    Curr Probl Dermatol; 2018; 53():15-27. PubMed ID: 29131034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Biologics in the Treatment of Moderate-to-Severe Plantar Psoriasis.
    Ekladios J; Jolliffe J; Panchigar S; Qureshi R; Shete A; Wellner J; Vlahovic TC
    Clin Podiatr Med Surg; 2021 Oct; 38(4):553-559. PubMed ID: 34538433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils.
    Yamanaka K; Umezawa Y; Yamagiwa A; Saeki H; Kondo M; Gabazza EC; Nakagawa H; Mizutani H
    J Dermatol; 2014 Aug; 41(8):679-85. PubMed ID: 25099154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can We Tell Patients That IL-23 and TNF-α Inhibition Are "Natural" Ways to Treat Psoriasis?
    Wechter T; Seger EW; Cline A; Feldman SR
    J Cutan Med Surg; 2019; 23(3):337-338. PubMed ID: 31070097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.